Form 8-K - Current report:
SEC Accession No. 0001493152-26-023200
Filing Date
2026-05-14
Accepted
2026-05-14 17:26:31
Documents
18
Period of Report
2026-05-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 55556
2 EX-4.1 ex4-1.htm EX-4.1 110977
3 EX-4.2 ex4-2.htm EX-4.2 113656
4 EX-4.3 ex4-3.htm EX-4.3 112676
5 EX-5.1 ex5-1.htm EX-5.1 13735
6 EX-10.1 ex10-1.htm EX-10.1 312624
7 EX-99.1 ex99-1.htm EX-99.1 20433
8 EX-99.2 ex99-2.htm EX-99.2 19340
  Complete submission text file 0001493152-26-023200.txt   1087638

Data Files

Seq Description Document Type Size
9 XBRL SCHEMA FILE ltrn-20260512.xsd EX-101.SCH 3029
10 XBRL LABEL FILE ltrn-20260512_lab.xml EX-101.LAB 34239
11 XBRL PRESENTATION FILE ltrn-20260512_pre.xml EX-101.PRE 22368
21 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3212
Mailing Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201
Business Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201 972-277-1136
Lantern Pharma Inc. (Filer) CIK: 0001763950 (see all company filings)

EIN.: 463973463 | State of Incorp.: TX | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39318 | Film No.: 26980606
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)